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Targeting the phosphoinositide 3-kinase isoform p110delta
impairs growth and survival in neuroblastoma cells
Abstract
PURPOSE: The phosphoinositide 3-kinase (PI3K)/Akt pathway is frequently activated in human cancer
and plays a crucial role in neuroblastoma biology. We were interested in gaining further insight into the
potential of targeting PI3K/Akt signaling as a novel antiproliferative approach in neuroblastoma.
EXPERIMENTAL DESIGN: The expression pattern and functions of class I(A) PI3K isoforms were
investigated in tumor samples and cell lines. Effects on cell survival and downstream signaling were
analyzed following down-regulation of p110alpha or p110delta in SH-SY5Y and LA-N-1 cells by
means of RNA interference. RESULTS: Overexpression of the catalytic p110delta and regulatory
p85alpha isoforms was detected in a panel of primary neuroblastoma samples and cell lines, compared
with normal adrenal gland tissue. Although down-regulation of either p110alpha or p110delta led to
impaired cell growth, reduced expression of p110delta also had a selective effect on the survival of
SH-SY5Y cells. Decreased levels of p110delta were found to induce apoptosis and lead to lower
expression levels of antiapoptotic Bcl-2 family proteins. SH-SY5Y cells with decreased p110delta levels
also displayed reduced activation of ribosomal protein S6 kinase in response to stimulation with
epidermal growth factor and insulin-like growth factor-I. CONCLUSIONS: Together, our data reveal a
novel function of p110delta in neuroblastoma growth and survival.
Targeting the Phosphoinositide 3-Kinase Isoform p110D Impairs
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Abstract Purpose: The phosphoinositide 3-kinase (PI3K)/Akt pathway is frequently activated in human
cancer and plays a crucial role in neuroblastoma biology.We were interested in gaining further
insight into the potential of targeting PI3K/Akt signaling as a novel antiproliferative approach in
neuroblastoma.
Experimental Design: The expression pattern and functions of class IA PI3K isoforms were
investigated in tumor samples and cell lines. Effects on cell survival and downstream signaling
were analyzed following down-regulation of p110a or p110y in SH-SY5Yand LA-N-1cells by
means of RNA interference.
Results: Overexpression of the catalytic p110y and regulatory p85a isoforms was detected in
a panel of primary neuroblastoma samples and cell lines, compared with normal adrenal gland
tissue. Although down-regulation of either p110a or p110y led to impaired cell growth, reduced
expression of p110y also had a selective effect on the survival of SH-SY5Ycells. Decreased levels
of p110y were found to induce apoptosis and lead to lower expression levels of antiapoptotic
Bcl-2 family proteins. SH-SY5Ycells with decreased p110y levels also displayed reduced activa-
tion of ribosomal protein S6 kinase in response to stimulation with epidermal growth factor and
insulin-like growth factor-I.
Conclusions:Together, our data reveal a novel function of p110y in neuroblastoma growth and
survival.
Neuroblastoma is the most common extracranial solid tumor
occurring in children and accounts for 8% to 10% of all
pediatric malignancies (1, 2). High-risk disease, present in
about half of the patients, is characterized by unresectable
primary lesions and metastasis (2). Treatment of high-risk
neuroblastoma with high-dose chemotherapy, including pe-
ripheral stem cell rescue and radiotherapy, resulted only in 34%
3-year event-free survival probability (3).
A better understanding of the biology of neuroblastoma will
potentially lead to the identification of novel therapeutic
targets, which in turn could facilitate the development of new
drugs for neuroblastoma. A promising field of investigation is
to target receptor tyrosine kinase (RTK) signaling to some of
their downstream mediators such as phosphoinositide 3-kinase
(PI3K), Akt, and the mammalian target of rapamycin (mTOR).
Polypeptide growth factors have indeed been shown to play a
key role in neuroblastoma biology. Insulin-like growth factor
(IGF) signaling has been extensively studied in the context of
neuroblastoma proliferation, survival, and motility (4–7).
Several potential antitumor approaches involving the IGF-I
system have been reported in neuroblastoma (8, 9). Moreover,
inhibition of platelet-derived growth factor receptor and c-Kit
signaling with imatinib mesylate was reported to impair growth
in neuroblastoma cell lines (10). Neurotrophins such as brain-
derived neurotrophic factor also play an important role in
neuroblastoma chemoresistance by binding to the Trk receptor
family (11).
In view of the fact that neuroblastoma express a variety of
different RTKs, it remains unclear whether targeting individual
receptors will provide a successful therapeutic strategy. An
alternative approach would be to identify downstream signal-
ing molecules essential for transmitting the proliferative and
survival message of several different RTKs. PI3K represents such
a molecule, in view of its crucial role in controlling cell
proliferation, survival, and motility/metastasis downstream of
many different RTKs (12–14). PI3Ks are an enzyme family
comprising eight catalytic isoforms in humans, with different
substrate specificities, regulatory mechanisms, and tissue
distribution (12, 14). The importance of PI3K signaling in
human cancer was first shown by the observation that
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mutations in the tumor suppressor gene PTEN occur frequently
in human tumors. PTEN is a phosphatase that antagonizes the
action of PI3K by dephosphorylating the D-3 position of
polyphosphoinositides (14, 15). Moreover, recent reports have
described activating mutations in the PIK3CA gene encoding
the catalytic p110a isoform of PI3K in a variety of human
cancers, including breast, colon, and ovarian cancer, as well as
medulloblastoma (16). In neuroblastoma, brain-derived neu-
rotrophic factor was shown to protect the tumor cells from
chemotherapy-induced apoptosis via the PI3K pathway (17).
IGF-I signaling via PI3K was shown to be required for
neuroblastoma differentiation, cytoskeletal rearrangements
(18), as well as angiogenesis and vascular endothelial growth
factor expression (19). PI3K signaling is also activated by
epidermal growth factor (EGF) in neuroblastoma cells and
contributes to cell proliferation by this growth factor (20).
Thus, targeting the PI3K/Akt/mTOR/S6 kinase (S6K) pathway
may represent an attractive novel approach to develop therapies
for neuroblastoma.
In the present report, we have evaluated the expression of
PI3K isoforms in primary human neuroblastoma samples and
cell lines. Moreover, we have investigated whether targeting
distinct PI3K isoforms could impair growth and survival of
neuroblastoma cell lines. Our results show for the first time that
the class IA PI3K p110y is overexpressed in a subset of
neuroblastoma samples and plays a crucial role in the growth
and survival of neuroblastoma cells.
Materials andMethods
Reagents and antibodies. Antibodies were purchased from the
following companies: p85a, p110h, p110y, poly(ADP)ribose polymer-
ase, PTEN, Akt/PKB, Erk1/2, Santa Cruz Biotechnology; S6 protein,
4EBP1 and phosphospecific antibodies for Akt/PKB (Ser473; Thr308),
Erk1/2 (Thr202/Tyr204), S6 protein (Ser235/236; Ser240/244), 4E-BP1
(Thr37/46), Cell Signaling Technology; h-actin, Sigma-Aldrich; p110a
(clone U3A), generous gift from Dr. A. Klippel (Atugen AG, Berlin,
Germany). Analysis of proteins involved in apoptosis was done using
the Pro-Survival and the Pro-Apoptosis Bcl-2 Family Antibody Sampler
Kit (Cell Signaling). LY294002, rapamycin, EGF, platelet-derived
growth factor, and IGF-I were obtained from Calbiochem.
Determination of PI3K-related gene expression in human primary
neuroblastoma samples by cDNA microarray analysis. The expression of
PI3K-related genes was determined in tumors from 68 neuroblastoma
patients by Affymetrix U95A array analysis. The patient cohort and data
normalization procedures have been described elsewhere (21). Corre-
lation of PI3K-related gene expression with molecular and clinical
variables was determined using the stats package included in R2.2.4
Visualization of gene expression was accomplished using Spotfire 8.1.
Primary neuroblastoma samples. Ethical approval to use residual
tissue was obtained. RNAlater-preserved tumor tissue was available
from the Swiss Pediatric Oncology Group tumor bank from neuroblas-
toma patients diagnosed between January 2003 and December 2005 at
the University Children’s Hospital of Zurich (n = 14), the Children’s
Hospital Luzern (n = 3), the University Children’s Hospital Bern
(n = 1), and the University Children’s Hospital Basel (n = 1). The
selection of the tumors for the study was based on the availability of a
sufficient quantity of tumor tissue to perform RNA isolation. All
diagnoses were confirmed by histologic assessment of the tumor
specimen obtained at surgery. An overview of the tumor characteristics
is given in Supplementary Fig. S1.
Protein extraction from tumor samples. Tumor tissue was disrupted
with a sterile disposable tissue grinder (Sage Products, Inc.). Protein
extracts were obtained using the PARIS Kit (Ambion) according to the
manufacturer’s instructions.
Isolation of RNA from tumor samples and reverse transcription-
PCR. Tumor tissue was disrupted as described above and homogenized
in guanidinium isothiocyanate-containing buffer. Total RNA was
isolated using the RNeasy kit (Qiagen, Inc.) according to the
manufacturer’s protocol. Total RNA (3 Ag) from each tumor sample
was converted into cDNA using the SuperScript First-Strand Synthesis
System for PCR according to manufacturer’s instructions (Invitrogen Life
Technologies). mRNA expression of four target genes and 18S (internal
control gene) was measured in tumor samples and cell lines by TaqMan
Assay-on-Demand Gene Expression products (Applied Biosystems).
Normal human adrenal gland tissue was used as a reference. The
following primers were used (gene assay ID): PIK3R1-Hs00236128_m1;
PIK3CA-Hs00180679_m1; PIK3CB-Hs00178872_m1; PIK3CD-
Hs00192399_m1; eukaryotic 18S rRNA-Hs99999901_s1. Three repli-
cates were run for each sample in a 96-well format plate. Gene expression
assays consisted of a FAM dye-labeled TaqManMGB probe and two PCR
primers. The thermal cycling conditions consisted of an initial
denaturation step at 95jC for 10 min and a 50-cycle countdown at
95jC for 15 s and 60jC for 1 min. Each sample was normalized on the
basis of its 18S rRNA content. Relative mRNA expression levels were
calculated using the comparative threshold cycle (CT) method (22).
Cell culture. Human neuroblastoma cell lines were kindly provided
by Dr. Brodeur (Children’s Hospital of Philadelphia, Philadelphia, PA).
The cells were grown in RPMI (Life Technologies/Invitrogen) supple-
mented with 10% (v/v) FCS and penicillin/streptomycin/L-glutamine,
and passaged every 3 to 5 days by trypsinization.
Stable transfectants. SH-SY5Y and LA-N-1 cells were stably trans-
fected with the murine ecotropic receptor (EcoR) using Lipofectamine
(Invitrogen) according to the manufacturer’s protocol. Seventy-two
hours posttransfection, cells were diluted in medium containing G418
(0.8 mg/mL). In parallel, retroviral plasmid constructs encoding short
hairpin RNA (shRNA) specifically targeting p110a or p110y (23) were
transiently transfected into packing cells. The supernatant was diluted
with one part RPMI containing G418 (final concentration: 0.8 mg/mL),
as well as polybrene (final concentration, 8 Ag/mL). The diluted
supernatant was then added to cells stably expressing EcoR. Twenty-four
hours postinfection, SH-SY5Y and LA-N-1 cells were split in medium
containing puromycin (0.5 Ag/mL). Single colonies were picked and
expanded in selective medium. Protein down-regulation was confirmed
by Western blot analysis. All experiments were done with two clones
from each transfection.
Transient transfection. Cells were transiently transfected using the
Amaxa Nucleofector Device according to the optimized protocol
provided for SH-SY5Y cells. The following constructs were used: pRS,
pRS-PIK3CA, pRS-PIK3CD (23), pcDNA3 (Invitrogen), and pcDNA-
S6K AK (9).
Cell proliferation. Neuroblastoma cells were seeded in 96-well
plates at a density of 7,500 per well and grown for 72 h in RPMI
containing low (1%) or high (10%) serum. Alternatively, cells were
treated with growth factors or inhibitors as indicated. Cell proliferation
was analyzed by the CellTiter 96 AQueous Cell Proliferation Assay
(Promega) according to the manufacturer’s instructions.
Apoptosis. Neuroblastoma cells were seeded in 96-well plates at a
density of 20,000 per well. Basal caspase-3/7 activity was measured after
24 h using the Caspase-Glo 3/7 Assay (Promega) according to the
manufacturer’s instructions.
Cell cycle distribution. Cell cycle distribution was analyzed by
means of propidium iodide staining and fluorescence-activated cell
sorting analysis. Cells were seeded in a six-well plate at a density of
6.5  105 and incubated in RPMI containing low (1%) or high (10%)
serum for 24 h. Cells were collected using 0.5% trypsin and
resuspended in cold PBS. One tenth volume of 10 propidium iodide
solution [500 Ag/mL propidium iodide, 10 mg/mL sodium citrate and4 http://www.r-project.org
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1% (v/v) Triton X-100] was added and cells were acquired in a flow
cytometer within half an hour.
Growth factor stimulations. Cells were grown to confluency in a six-
well plate and starved overnight in RPMI containing 0.5% FCS. Cells
were maintained in serum-free RPMI for 1 h in the presence or absence
of inhibitors as indicated and were then stimulated with the indicated
growth factors for 10 min. Cellular lysates were prepared as described
below.
Western blotting. Cellular lysates were prepared as described (24)
and normalized using a bicinchoninic acid protein assay (Pierce). Cell
lysates were separated by SDS-PAGE, transferred to a hydrophobic
polyvinylidene difluoride membrane (Hybond-P; Amersham Bioscien-
ces), and immunoblotted with the indicated antibodies before
chemiluminescent detection (ECL Western blotting detection reagents;
Amersham Biosciences).
Statistical analysis. Spearman’s rank correlation and the exact
Wilcoxon’s rank-sum test were used for the analysis of PI3K gene
expression in primary neuroblastoma samples. For experiments on cell
lines, the statistical significance of differences between groups was
assessed with ANOVA using Bonferroni’s multiple comparison test; P <
0.01 was indicated with a double asterisk.
Results
Overexpression of PI3K isoforms in primary human neuro-
blastoma samples and cell lines. To gain insight into the
specific functions of class IA PI3K isoforms in neuroblastoma,
we initially assessed the expression levels of the regulatory and
catalytic subunits in two independent groups of tumor
samples. In a panel of 19 primary neuroblastoma samples,
the expression levels of the class IA PI3K regulatory and
catalytic subunits were analyzed by quantitative reverse
transcription-PCR (Fig. 1A). Expression of the PIK3R1
(encoding the regulatory subunit p85a) and PIK3CD (encod-
ing the catalytic subunit p110y) genes was found to be
increased >2-fold in 10 of 19 neuroblastoma samples when
compared with normal adrenal gland tissue (Fig. 1A, left). In
contrast, mRNA expression of the catalytic p110a and p110h
isoforms was not increased (Fig. 1A, left). In this panel of
tumor samples, expression of p85a and p110y was signifi-
cantly correlated (Spearman’s rank correlation, P < 0.0001),
indicating that the p85a/p110y heterodimer is overexpressed
in neuroblastoma. Expression of p85a and p110y was
significantly higher in children under the age of 1 year
(median values, 2.48 for p85a and 5.17 for p110y) than in
patients older than 1 year old (median values, 0.64 for p85a
and 0.95 for p110y; exact Wilcoxon’s rank-sum test, P =
0.0121 for p85a; P = 0.0025 for p110y). Furthermore, the
expression of p85a and p110y was found to be significantly
lower in neuroblastoma samples with MYCN amplification
(median values, 2.42 for p85a and 4.63 for p110y) than
without amplification (median values, 0.81 for p85a and 0.75
for p110y; exact Wilcoxon’s rank-sum test, P = 0.0339 for
p85a; P = 0.0339 for p110y). In contrast, no correlation was
found between p85a and p110y expression and tumor stage,
1p status, or progression. Thus, p85a and p110y expression
was found to be increased in neuroblastoma samples from
children under the age of 1 year and with no MYCN
amplification.
To investigate if PIK3CD mRNA levels are predictive of
protein expression levels, Western blot analysis was done on 12
of the patient samples. In 10 of 12 samples, mRNA levels
correlated with protein expression (Fig. 1A, right).
Reanalysis of cDNA microarray data of an independent panel
of 68 primary neuroblastoma samples also revealed striking
variations in the expression levels of the class IA PI3K regulatory
subunit p85a and the catalytic subunit p110y. Expression of the
p85a and p110y subunits was significantly higher in samples
from children under the age of 1 year compared with patients
older than 1 year old (Fig. 1B), confirming the results of the
quantitative reverse transcription-PCR analysis (Fig. 1A).
We next investigated the expression of PI3K isoforms in a set
of eight representative neuroblastoma cell lines to validate the
findings obtained in tumor samples. In this panel of cell lines,
p85a was overexpressed in five of eight samples, whereas the
catalytic isoforms p110a, p110h, and p110y showed increased
expression in four of eight, six of eight, and one of eight cell
lines, respectively (Fig. 1C, left). In line with the findings in
patient samples, cell lines harboring MYC amplification
showed decreased levels of PIK3CD mRNA when compared
with adrenal tissue (Fig. 1C, left). As with the patient samples,
mRNA levels were largely found to be predictive of protein
levels (Fig. 1C, right).
The expression of PI3K isoforms was next investigated at the
protein level in a panel of eight neuroblastoma cell lines. All
neuroblastoma cell lines included in this study expressed the
p85a, p110a, and p110h isoforms, whereas the expression
of p110y was more variable, being highest in SH-SY5Y cells
(Fig. 2A). Together, these data show that the expression levels
of PI3K isoforms are altered in neuroblastoma samples and cell
lines at the mRNA and/or protein level, and that the expression
of the catalytic p110y isoform is increased in neuroblastoma.
Activation of PI3K/Akt signaling by polypeptide growth factors
in neuroblastoma cell lines. Class IA PI3Ks transduce signals
from activated RTKs to downstream effectors, the most
important of which is the Ser/Thr protein kinase Akt (12, 13).
The activation of Akt by polypeptide growth factors was
investigated in SH-SY5Y and LA-N-1 cells. EGF and IGF-I most
potently activated Akt in SH-SY5Y cells, whereas platelet-derived
growth factor and IGF-I induced the strongest response in LA-N-
1 cells (Fig. 2B).
EGF and IGF-I stimulated growth of SH-SY5Y (2- and 2.5-
fold) and LA-N-1 (2- and 2.2-fold) cells, whereas platelet-
derived growth factor was less potent at promoting a growth
response (Fig. 2C). The pharmacologic PI3K inhibitor
LY294002 reduced basal growth of SH-SY5Y (66.5% inhibi-
tion) and LA-N-1 (42.8% inhibition) cells. Treatment with the
PI3K inhibitor also reduced EGF- and IGF-I–stimulated growth
in SH-SY5Y (44.1% and 27.6% inhibition, respectively) and
LA-N-1 cells (Fig. 2C). However, LY294002 as a single agent
did not significantly affect the extent of growth factor–
stimulated cell growth in either SH-SY5Y or LA-N-1 cells
(Fig. 2C). Recently, a similar observation was reported in
neuroblastoma cell lines, where the combination of both
LY294002 and the mTOR inhibitor rapamycin was required to
inhibit IGF-I–induced proliferation (9). Thus, various growth
factors, including EGF and IGF-I, stimulate growth of neuro-
blastoma cells via the PI3K/Akt pathway.
Impact of shRNA-mediated down-regulation of p110a and
p110d on neuroblastoma cell proliferation and apoptosis. To
gain insight into the individual functions of class IA PI3K
isoforms in neuroblastoma cell responses, SH-SY5Y and LA-N-1
cells were stably transduced with short hairpin RNA (shRNA)
constructs targeting p110a (hereinafter p110alow) or p110y
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(hereinafter p110ylow). Specific down-regulation of target gene
expression was verified by Western blot analysis (Fig. 3A). The
growth of SH-SY5Y p110ylow cells was significantly reduced
(53.1% and 44.1% inhibition) when the cells were cultivated in
medium containing low (1%) serum, but not high (10%),
serum (Fig. 3B). This effect was less pronounced in LA-N-1 cells
(Fig. 3B), correlating with the differential expression of p110y
in these cell lines. Although an effect of p110a down-regulation
was also observed in SH-SY5Y cells (low serum, no inhibition
or 21.3% inhibition; high serum, no inhibition or 21.2%
inhibition), the effect was stronger in LA-N-1 cells (low serum,
22.1% and 66.4% inhibition; high serum, 11.7% and 43.4%,
inhibition).
To investigate whether PI3K targeting promoted apoptosis in
neuroblastoma cells, caspase activity and cell cycle distribution
were analyzed in SH-SY5Y p110alow or p110ylow cells. A
significant (2.2-fold) increase in caspase-3/7 activity was
observed in SH-SY5Y p110ylow cells (Fig. 3C). In contrast, a
comparable response was not observed in SH-SY5Y p110alow
cells (Fig. 3C). Analysis of cell cycle distribution revealed a
Fig. 1. Expression of class IA PI3K genes in neuroblastoma patient samples and cell lines. A,TaqMan analysis of class IA PI3K mRNA levels in neuroblastoma patient samples
(n = 19) and human adrenal gland (AG). Black columns, PIK3R1; light gray columns, PIK3CA ; white columns, PIK3CB ; dark gray columns, PIK3CD (left).Western blot of
p110y expression in patient samples (n = 12) and adrenal gland compared withTaqMan data (right). B, box plot visualizing p85a and p110y expression in an additional,
independent group of 68 human neuroblastoma samples. C, analysis of class IA PI3K mRNA levels in human neuroblastoma cell lines (n = 8) and adrenal gland. Color code
according toA (left).Western blot of p110y expression in cell lines (n = 8) and adrenal gland compared withTaqMan data (right).
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decrease in the S phase in SH-SY5Y p110alow and p110ylow
cells, both in low serum (61.8% decrease in both cases) and
high serum (71.4% and 59.2% decrease). The increase in cell
death under low serum conditions was higher in SH-SY5Y
p110ylow cells (319.4% increase) than in SH-SY5Y p110alow
cells (64.5% increase), confirming the results of the caspase
assay (Fig. 3C). Together, these results show that the p110y
isoform plays a major role in SH-SY5Y cell growth and survival
under suboptimal culture conditions. In contrast, a comparable
role was not apparent for p110a in these cells, although this
isoform appeared to play a more important function in LA-N-1
cells, which express only very low levels of p110y.
In view of the increased apoptosis observed in SH-SY5Y
p110ylow cells, we analyzed the expression of proapoptotic and
antiapoptotic Bcl-2 family proteins, which are key regulators of
apoptosis. The levels of Bcl-2 and Bcl-XL were elevated in
SH-SY5Y cells grown in high serum, compared with low serum
conditions (Figs. 3D and 5B). When compared with control
cells, SH-SY5Y p110ylow cells displayed reduced expression of
the antiapoptotic proteins Bcl-2 and Bcl-XL (Figs. 3D and 5B).
In contrast, the levels of Bax were unaffected (Fig. 3D). Thus,
p110y seems to contribute to the control of the expression of
antiapoptotic Bcl-2 family proteins, which may affect its
function in neuroblastoma cell survival.
Impact of shRNA-mediated down-regulation of p110a and
p110d on neuroblastoma cell responses to growth factors. We
next investigated the involvement of class IA PI3K isoforms in
polypeptide growth factor signaling in neuroblastoma cells. The
ability of EGF and IGF-I to stimulate the growth of SH-SY5Y
cells was significantly reduced in both SH-SY5Y p110alow and
p110ylow cells (EGF, 6.4% and 40.3%, 23.4%, and 16.2%,
respectively; IGF-I, 27.5% and 41.5%, 42.1% and 49.1%,
respectively; Fig. 4A). In contrast, the ability of EGF and IGF-I
to stimulate the growth of LA-N-1 p110alow and p110ylow cells
was not significantly impaired (Fig. 4A).
The effect of the shRNA constructs targeting p110a and
p110y on the activation of early signaling mediators of RTKs
was then investigated in SH-SY5Y and LA-N-1 cells. Activation
of Akt by EGF and IGF-I was unaltered in SH-SY5Y and LA-N-1
cells (Fig. 4B; Supplementary Fig. S2). In contrast, activation of
the mTOR/S6K pathway by EGF and IGF-I was impaired in
both SH-SY5Y p110alow and p110ylow cells, as assessed by
phosphorylation of the S6 protein (Fig. 4B). Although the effect
of p110a down-regulation on signal transduction was expected,
the observation that decreased p110y expression leads to a
comparable effect on its own was surprising. Activation of Erk1/
2 by EGF and IGF-I was unaffected by the PI3K shRNAs (data
not shown). Thus, p110y plays an important role in activation
of the mTOR/S6K pathway in SH-SY5Y cells, which correlates
with its involvement in neuroblastoma cell growth. However,
activation of Akt by growth factors is insensitive to down-
regulation of a single PI3K isoform in these cells. This is not
unexpected, as previous studies have reported that PI3K
isoforms from other classes contribute to Akt activation (24).
In both LA-N-1 p110alow and p110ylow cells, basal activation of
Akt and S6K was reduced (Supplementary Fig. S2). However, in
LA-N-1 cells, phosphorylation of the S6 protein was hardly
affected by down-regulation of p110y (Supplementary Fig. S2).
Although decreased p110a expression led to a stronger
inhibition of downstream signaling, no apparent effect on the
proliferative response was observed, suggesting that other
pathways may compensate for reduced signal transduction in
this cell line (Fig. 4A; Supplementary Fig. S2).
Constitutive activation of the S6K pathway abrogates the effect
of p110d shRNA on SH-SY5Y cell growth. Our previous data
had shown a marked effect of p110y down-regulation by
shRNA on activation of the mTOR/S6K pathway in SH-SY5Y
cells, contributing to cell growth. To confirm this model, SH-
SY5Y p110ylow cells were transiently transfected with an
activated mutant of S6K1. Activated S6K promoted growth
of SH-SY5Y cells and was able to partially rescue the growth of
SH-SY5Y p110ylow cells (Fig. 5A). However, the induction of
apoptosis induced by the p110y shRNA was only marginally
impaired by S6K transfection, as assessed by cleavage of
Fig. 2. PI3K class IA isoform expression
and growth factor ^ induced pathway
activation inhumanneuroblastoma cell lines.
A, expression pattern of PI3K isoforms, Akt,
and the PI3K antagonist phosphatase and
tensin homologue (PTEN) in human
neuroblastoma cell lines. B, growth factor ^
induced pathway activation in SH-SY5Yand
LA-N-1cells. C, effect of LY294002 on
growth factor ^ stimulated proliferation.
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poly(ADP-ribose) polymerase (Fig. 5B). Moreover, transient
transfection of activated S6K did not restore the levels of Bcl-2
and Bcl-XL in SH-SY5Y p110y
low cells (Fig. 5B). Together, these
results show that the PI3K p110y isoform controls neuroblas-
toma cell growth via the S6K pathway. In addition, it also seems
to play a role in controlling the levels of Bcl-2 family proteins,
which seems not to involve S6K or Akt.
Rapamycin mimics the effects of p110d down-regulation. The
data presented above highlighted the importance of signaling via
the mTOR/S6K pathway in the regulation of neuroblastoma cell
survival and the ability to respond to growth factors. To confirm
these findings, SH-SY5Y and LA-N-1 cells were treated with
rapamycin, a mTOR inhibitor, and cellular responses were
investigated. As expected, phosphorylation of the S6 protein
was abrogated in the presence of rapamycin, both in low (1%)
and high (10%) serum conditions (Fig. 6A). Treatment of
SH-SY5Y and LA-N-1 cells with rapamycin led to a dose-
dependent inhibition of basal cell proliferation [SH-SY5Y,
29.2% (20 ng/mL) and 56.6% (100 ng/mL) inhibition; LA-N-1:
37.3% (20 ng/mL) and 61.8% (100 ng/mL) inhibition; Fig. 6B].
Cotreatment of cells with rapamycin attenuated the proliferative
response to EGF [SH-SY5Y, 34.7% (20 ng/mL) and 55.8%
(100 ng/mL) inhibition; LA-N-1, 32.5% (20 ng/mL) and 44.4%
(100 ng/mL) inhibition] and IGF-I [SH-SY5Y, 32.5% (20 ng/mL)
and 53% (100 ng/mL) inhibition; LA-N-1, 27.7% (20 ng/mL)
and 42.1% (100 ng/mL) inhibition; Fig. 6B]. Furthermore,
phosphorylation of the S6 protein was found to be absent upon
stimulation with EGF or IGF-I in cells pretreated with rapamycin
(Fig. 6C). These findings emphasize the importance of intact
mTOR/S6K signaling in neuroblastoma cell survival.
Discussion
In recent years, PI3K has emerged as a central controller of
the cellular responses to a variety of growth factors and PI3K
signaling is frequently deregulated by diverse mechanisms in
Fig. 3. Effect of class IA PI3K isoform down-regulation on cell proliferation and cell death in human neuroblastoma cells.A,Western blot analysis of protein down-regulation
in SH-SY5Yand LA-N-1cells stably transfected with shRNA against p110a (PIK3CA) or p110y (PIK3CD) or the control vector (pRS). B, basal proliferation of SH-SY5Yor
LA-N-1cells inmedium containing low (1%) or high (10%) serum.C, basal caspase-3/7 activity of SH-SY5Yclones inmedium containing low (1%) or high (10%) serum (left).
Cell cycle distribution of SH-SY5Yclones in medium containing low (1%) serum. Black fraction, dead cells; dark gray fraction, G2 phase; white fraction, S phase; light gray
fraction, G0-G1phase (right). D,Western blot analysis of the expression levels of proteins involved in apoptosis in SH-SY5Ycells stably transfected with shRNA against
p110y (PIK3CD) or the control vector (pRS) under low (1%) and high (10%) serum conditions.
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human cancer (14, 16). PI3K has also been shown to play an
important role in neuroblastoma biology. Therefore, targeting
PI3K may represent an attractive approach to inhibit
neuroblastoma proliferation in vivo (11, 17, 18, 25).
However, the mechanisms contributing to the activation of
PI3K signaling in neuroblastoma are still unclear, because loss
of PTEN or PIK3CA mutations are uncommon in this
pediatric malignancy (26–28). We show here for the first
time that the class IA PI3K isoform p110y plays a crucial role
in neuroblastoma cell growth and survival and that the
expression of p110y is increased at the mRNA and protein
level in a subset of primary neuroblastoma samples and cell
lines. In addition, our data reveal a selective expression of
p85a/p110y in neuroblastoma samples from children under
the age of 1 year. Our results also reveal a negative correlation
between PIK3CD gene expression and MYCN amplification.
Expression of PIK3CD was recently shown to be significantly
lower in neuroblastoma samples with loss of heterozygosity at
1p36 (29). A recent study also described a correlation
between decreased PIK3CD expression, 1p deletion, and poor
clinical outcome (30). Loss of heterozygosity at 1p36 was
associated with amplification of the MYCN oncogene (31).
Reduced expression of PIK3CD in neuroblastoma samples
may thus correlate with poor prognosis, due to its association
with age at diagnosis (>1 year), LOH at 1p36, and/or MYCN
amplification, because these events are prognostic markers of
poor outcome in neuroblastoma (1, 2, 31, 32). N-Myc was
shown to be able to replace IGF/PI3K signaling in medullo-
blastoma formation (33). Moreover, c-Myc expression had a
negative effect on the activation of PI3K/Akt signaling (34).
Thus, it is conceivable that MYCN-amplified neuroblastoma
display decreased PIK3CD expression, either because of (a)
loss of heterozygosity at 1p36 (29), (b) a direct negative effect
of MYCN amplification on PIK3CD expression, or (c) because
they are less dependent on p85a/p110y signaling. Collective-
ly, these data indicate that the class IA p110y isoform may
play a role in the development of neuroblastoma in very
young patients (<1 year old) or in a subset of tumors that do
not harbor loss of heterozygosity at 1p36 and/or MYCN
amplification.
Fig. 4. Proliferative response and pathway
activation upon growth factor stimulation
in cells expressing decreased levels of p110a
or p110y. A, growth factor ^ induced
proliferation of SH-SY5Yand LA-N-1cells
stably transfected with shRNA against
p110a (light gray columns) or p110y
(dark gray columns) or the control vector
pRS (black columns). B, growth factor ^
induced activation of the PI3K pathway in
SH-SY5Yp110alow (PIK3CA) or p110ylow
(PIK3CD) cells compared with control
cells (pRS).
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The expression of p110y was previously shown to be
predominantly restricted to leukocytes in normal tissues (35).
However, different human cancer cell lines were also shown to
express this PI3K isoform, indicating that aberrant expression of
p110y in tumors may contribute to the malignant properties
of the cancer cells (24, 36). In support of this notion, the ability
of p110y to induce transformation of chicken fibroblasts was
recently shown (37). In breast cancer cell lines, a selective
function of p110y in cell migration was also described (36). In
acute myeloid leukemia, recent reports have shown that p110y
plays a major role in activation of Akt by RTKs (FLT3), cell
proliferation, and chemoresistance (38, 39). We show here that
the class IA PI3K isoforms p110a and p110y do not have
overlapping functions in neuroblastoma cell responses. Indeed,
in SH-SY5Y cells that display increased PIK3CA and PIK3CD
expression, p110y seemed to play a major role in controlling
neuroblastoma cell growth and survival under limiting growth
conditions. In contrast, in LA-N-1 cells with only very low
p110y expression, down-regulation of p110a by shRNA
impaired cell growth and Akt activation. The effect of p110y
down-regulation by shRNA on SH-SY5Y growth correlated with
an impairment of the activation of the mTOR/S6K pathway.
Fig. 5. Constitutively activated S6K can
partially rescue SH-SY5Ycells from cell
death induced by p110y down-regulation.
A, proliferative response of SH-SY5Y
p110ylow cells (PIK3CD) transiently
transfected with constitutively activated S6
kinase1 (S6K AK1) or the control vector
(pcDNA3). B,Western blot analysis of the
expression levels of proteins involved in
apoptosis (Bcl2, Bcl-XL, Bax) and
poly(ADP-ribose) polymerase (PARP)
cleavage.
Fig. 6. Rapamycinmimics the effect of p110y down-regulation.A,Western blot analysis of S6
protein phosphorylation upon treatment of SH-SY5Yand LA-N-1cells with rapamycin.
B, proliferation of SH-SY5Yand LA-N-1cells in response to EGF and IGF-I upon
cotreatment with rapamycin (ng/mL where indicated). C,Western blot analysis of S6 protein
phosphorylation in response to stimulation with EGF or IGF-I upon pretreatment with
rapamycin.
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Surprisingly, Akt activation by EGF and IGF-I was unaffected by
p110y down-regulation, under conditions where the mTOR/
S6K pathway was inhibited. Thus, activation of Akt and
mTOR/S6K have different sensitivities to class IA PI3K down-
regulation. It is conceivable that other PI3K isoforms may
compensate for p110a or p110y in growth factor–stimulated
Akt activation (24). Transfection of an activated mutant of S6K
was sufficient to partially rescue the growth defect of SH-SY5Y
p110ylow cells under low serum conditions. However, p110y
seemed to have an additional function in maintaining the
levels of antiapoptotic Bcl-2 family proteins in neuroblastoma
cells, which did not involve S6K or Akt. The observation that
the expression levels of antiapoptotic Bcl-2 family proteins
were higher in SH-SY5Y under high serum conditions than in
low serum indicates that growth factors contribute to the
regulation of the levels of Bcl-2 family proteins in these cells.
Previous reports have documented a role for IGF-I, which is
present in the FCS, in maintaining Bcl-2 (40) and Bcl-XL (41)
expression levels. In view of the data presented here showing a
role for p110y in IGF-I signaling in neuroblastoma cells, it can
be postulated that IGF-IR/p110y contributes to regulation of
the expression of Bcl-2 family proteins. Because Akt and S6K
were not involved in this pathway, the simplest explanation
for these observations is that mTOR-mediated phosphoryla-
tion of 4E-BP1 controls translational activation of the
expression of Bcl-2 and/or Bcl-XL in neuroblastoma cells,
which is supported by previous findings in other systems (42).
Down-regulation of p110a by shRNA had a less pronounced
effect on the growth of SH-SY5Y cells under low serum
conditions, although activation of S6K was impaired. In view
of the observation that p110a down-regulation did not induce
apoptosis in SH-SY5Y cells, in contrast to p110y, it can be
speculated that Bcl-2 family proteins are selectively controlled
by the p110y isoform.
Together, our results show that p110y contributes to
neuroblastoma cell growth and survival by regulating the
activation of the mTOR/S6K pathway and the expression levels
of antiapoptotic Bcl-2 family proteins.
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